Alternatives in Magnesium Sulfate Treatment Courses: An Investigation of Physician Prescribing Behaviors by Williams, Erin
University of Missouri, St. Louis
IRL @ UMSL
Dissertations UMSL Graduate Works
7-11-2018
Alternatives in Magnesium Sulfate Treatment
Courses: An Investigation of Physician Prescribing
Behaviors
Erin Williams
elwpf4@mail.umsl.edu
Follow this and additional works at: https://irl.umsl.edu/dissertation
Part of the Maternal, Child Health and Neonatal Nursing Commons
This Dissertation is brought to you for free and open access by the UMSL Graduate Works at IRL @ UMSL. It has been accepted for inclusion in
Dissertations by an authorized administrator of IRL @ UMSL. For more information, please contact marvinh@umsl.edu.
Recommended Citation
Williams, Erin, "Alternatives in Magnesium Sulfate Treatment Courses: An Investigation of Physician Prescribing Behaviors" (2018).
Dissertations. 782.
https://irl.umsl.edu/dissertation/782
Alternatives in Magnesium Sulfate Treatment Courses: An Investigation of Physician 
Prescribing Behaviors 
 
 
 
Doctor of Nursing Practice Project Presented to the 
 
Faculty of Graduate Studies 
 
University of Missouri – St. Louis 
 
 
 
In Partial Fulfillment of the Requirements 
 
For the Degree of Doctor of Nursing Practice 
 
by 
 
Erin L. Williams, BSN, RNC-MNN 
 
 
 
DNP Committee Chair: Nancy Magnuson, DNS, CS, FNP-BC, RN 
 
DNP Committee Member: Roberta Lavin, Ph.D., FNP-BC, FAAN 
 
DNP Committee Member: Roxanne Vandermause, PhD, RN 
 
DNP Committee Member: Heidi Tymkew, PT, DPT, MHS, CSS 
 
Graduation August 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alternatives in Magnesium Sulfate Treatment Courses 
 
2 
Abstract 
Problem: The gold standard for managing preeclampsia in the postpartum patient is 24-
hours of magnesium sulfate as this is the time the patient is most susceptible to 
experiencing a seizure (American College of Obstetricians & Gynecologists, 2013). 
However, these patients are at an increased risk for experiencing adverse health outcomes, 
as well as interruptions in maternal-infant bonding due to the mother requiring a higher 
level of care. 
Methods: A one group pretest-posttest design was conducted to gain a better 
understanding of the current practice while also assessing the willingness of physicians to 
change prescribing behavior after receiving the research-based education.  
Results: During the study period, 49 obstetric providers agreed to participate in the study. 
There was no statistically significant difference between survey results regarding 
likelihood to prescribe a reduced course of magnesium sulfate (p=.821). However, there 
was a statistically significant difference seen between the perception that 24-hours of 
magnesium sulfate is necessary to manage preeclampsia (p=.020) and the theory that 
patients with preeclampsia without severe features could benefit from an abbreviated 
treatment course (p=.012). 
Implications for Practice: While data results do not indicate an immediate change in the 
prescribing of magnesium sulfate, physicians expressed interest in continued efforts to 
study this topic. There is an opportunity to improve patient safety by standardizing patient 
education. Additionally, a discrepancy was noted between the physicians’ perceptions of 
the postpartum acuity of the preeclamptic patient. Bridging the gap between nursing and 
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providers ensures that providers have a reasonable expectation of the postpartum 
experience. 
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Introduction 
Preeclampsia is a leading cause of maternal morbidity and preterm labor contributing 
to 9%-26% of life-threatening maternal outcomes globally (Townsend, O’Brien, Khalil, 
2016, p. 79). The American College of Obstetricians and Gynecologists (2013) defines 
preeclampsia as a blood pressure higher than 140/90 on two separate accounts at least 
four hours apart in a previously normotensive woman after 20 weeks’ gestation and 
proteinuria (p. 4). Preeclampsia can also be diagnosed with hypertension after 20 weeks’ 
gestation in the absence of proteinuria, but with signs of multiple organ involvement 
resulting in thrombocytopenia, renal insufficiency, and impaired liver function (ACOG, 
2013, p. 4). The American College of Obstetricians and Gynecologists (2013) has 
identified magnesium sulfate infusions to be the gold standard in preventing seizures in 
patients with preeclampsia (2013, p. 6).  However, prolonged durations of magnesium 
sulfate is shown to increase the risk of blood clots due to increased time to ambulation, 
increased risk of urinary tract infections related to the duration of indwelling catheter, and 
interrupting of maternal-infant bonding due to the mother needing higher-level care 
resulting in the delay in breastfeeding (Maia, Katz, Neto, Caiado, Azevedo & Amorim, 
2014, p. 260). Traditionally, preeclampsia is treated with a magnesium sulfate infusion 
for the first 24-hours after delivery since that is the period the patient is most susceptible 
to experiencing seizures related to high blood pressures (Maia et al., 2014, p. 260). 
However, current literature suggests that a 12-hour treatment course of magnesium 
sulfate can be as practical as a 24-hour treatment course in preventing seizures in low-risk 
preeclamptic patients (Anjum, Goel, Sharma, Mohsin, & Garg, 2016, p. 68; Kashanian, 
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Koohpayehzadeh, Sheikhansari, Barapour, Sahraian, & Asadolla, 2016, p. 2282; Maia et 
al., 2014, p. 260).  
This project took place within the obstetric (OB) department on a sizeable academic 
campus located in the city. The majority of patients cared for on these units come from 
low-income, underserved areas of St. Louis (Barnes-Jewish Hospital, 2017). 
Demographically, this community is primarily black accounting for 96.8% of its residents 
(Statistical Atlas, 2015). There is data to support that when compared to Caucasians, 
African Americans are at higher risk of experiencing preeclampsia (Breathett, 
Muhlestein, & Gulati, 2014, p. 886). In addition to race other risk factors include 
“women who are …primigravida, have multiparous pregnancy, prior history of 
preeclampsia, aged 35 years or older, and those who have existing chronic hypertension, 
diabetes, chronic kidney disease, obesity, or connective tissue disorder” (Breathett, 
Muhlestein, & Gulati, 2014, p. 887).  
Anjum et al. (2016) acknowledge the financial impact this treatment has on not only 
the medical facility but also the patient (p. 71). Knowing the financial strains faced by 
this patient population a change in the protocol can result in benefits for the patient 
financially, as well as physiologically. Prescribing an abbreviated treatment course of 
magnesium sulfate could result in effectively preventing seizures in low-risk postpartum 
patients with preeclampsia while also improving clinical outcomes, increasing patient 
satisfaction, and reducing treatment costs.  Recognizing that changing magnesium 
treatment time from 24-hours to 12-hours would be a significant change in practice, 
assessing the physicians’ willingness to change prescriptive behavior will be a critical 
first step to what could develop into a larger research project for the future.  The purpose 
Alternatives in Magnesium Sulfate Treatment Courses 
 
6 
of this project is to determine whether implementation of a research-based educational 
session for OB physicians, to discuss new knowledge related to abbreviated magnesium 
sulfate treatment of preeclampsia in postpartum patients, results in the participating OB 
physicians’ willingness to change the current practice of prescribing magnesium sulfate 
infusion for a 24-hour period to an abbreviated 12-hour period in preeclamptic 
postpartum patients.  
Review of Literature  
 A thorough database search was conducted including PubMed, CINAHL, and 
Scopus. The search was limited to the five-year period from 2012-2017, to reflect the 
most current and relevant literature. Search words included magnesium sulfate, 
randomized controlled trials, meta-analysis, preeclampsia, postpartum, infusions, drug 
administration schedule, puerperal disorders, treatment outcome, postnatal care, 
postpartum care, bed rest, and duration. Inclusion criteria included randomized controlled 
trials. Additionally, articles that were not peer-reviewed, scholarly articles with 
nonpertinent titles and abstracts, as well as articles that were not available in full-text 
were excluded.  
  The primary concern was postpartum patients with preeclampsia treated with 
magnesium sulfate remaining on strict bed rest. On the postpartum unit at Barnes-Jewish 
Hospital, it was once expected that these patients remain on strict bed rest for multiple 
reasons. Having preeclampsia predisposes patients to become eclamptic, or having 
seizures. Patients with preeclampsia are kept on seizure precautions while on a 
magnesium sulfate infusion requiring oxygen and suction to be readily available. 
Furthermore, magnesium sulfate acts as a smooth muscle relaxer placing these patients at 
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risk for falls (Murray & McKinney, 2010, pp. 637-638). As of recently, physicians were 
beginning to allow patients on magnesium sulfate to leave the patient care unit without 
nurse supervision, and without oxygen and suction readily available. Unfortunately, there 
was no literature available to support the need for strict bed rest for patients treated with 
magnesium sulfate which resulted in a change in search strategies to address this problem 
from a different perspective. Further concerns for patients treated with magnesium sulfate 
is the length of time with a Foley catheter, which increases the risk for urinary tract 
infections, the period to ambulation, and length of time to maternal-infant bonding (Maia 
et al., 2014, p. 260). Utilizing these critical concerns as search strategies introduced the 
topic of abbreviated treatment courses of magnesium sulfate in preventing seizures in 
postpartum women with preeclampsia.  
 There is currently no standard recommendation for the length of time a patient 
with preeclampsia should be treated with magnesium sulfate to prevent seizures (Anjum 
et al., 2016a, p. 68). However, preeclampsia is traditionally treated for the first 24-hours 
after delivery because that is the period the patient is most at risk for experiencing 
(Anjum et al., 2016a, p. 68; Darngawn, Jose, Regi, Bansal, & Jeyaseelan, 2012, p. 237; 
Maia et al., 2014, p. 260). Throughout the literature, several approaches were taken 
regarding reducing treatment time. Chama, Geidam, Bako, Mairiga & Atterwahmie 
(2013) was unique in that the preferred method of administration was by intramuscular 
injection (IM) and utilized the Pritchard method (p. 131). The Pritchard method involves 
the patient receiving an initial loading dose of 4 grams of magnesium sulfate by 
intravenous (IV) infusion along with a 5-gram magnesium sulfate IM injection into each 
buttock then followed by an additional 5-gram magnesium sulfate IM injection in each 
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buttock, alternating sides, every four hours until the 24-hour mark is reached (Chama et 
al., 2013, p. 132). Chama et al. (2013) argued that a shortened course of magnesium 
sulfate would be as efficient as the standard Pritchard method at preventing seizures (p. 
131). A reduced course included the loading dose of 10 mg IV magnesium sulfate 
followed by only two magnesium sulfate IM injections into each buttock four hours apart 
(Chama et al., 2013, p. 132). It was determined that this shortened treatment course was 
as useful as the Pritchard method in preventing seizures in the first 24-hours after 
delivery (p=0.684) while also exhibiting similar “maternal and perinatal outcomes” and 
reducing the total dose of magnesium sulfate by more than 40%” (Chama et al., 2013, p. 
133). 
 Previous research has shown that the loading dose of magnesium sulfate alone 
could be useful in preventing seizures in the first 24-hours after delivery (Anjum et al., 
2016a, p. 68; Anjum, Rajaram, & Bano, 2016, p. 983). However, a theme of reducing 
treatment time to 6-hours was more common. Anjum et al. (2016b) compared patients 
receiving the traditional 24-hour treatment course to patients who received an abbreviated 
6-hour treatment course of magnesium sulfate. Study groups were found to be 
comparable with no statistically significant differences in demographic or clinical 
characteristics (Anjum et al., 2016b, p. 984). Moreover, neither group exhibited seizures 
after completion of treatment (Anjum et al., 2016, p. 984). There was no difference 
between study groups concerning perinatal or neonatal outcomes (Anjum et al., 2016, p. 
985). However, statistically significant differences were seen in the intervention group 
regarding maternal outcomes as illustrated by decreases in the dose of magnesium sulfate 
given Group A 15.1 ± 5.4, Group B 42.3 ± 7.3; p<0.001) time with a Foley catheter 
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(Group A 11.3 ± 5.1, Group B 38.3 ± 7.3; p<0.001), and hours of monitoring (Group A 
11.1 ± 4.7, Group B 38.4 ± 7.2; p<0.001) (Anjum et al., 2016, p. 985). Darngawn, Jose, 
Bansal & Jevaseelan (2012) did similar work in reducing treatment time from 24-hours to 
6-hours (p. 237). The intervention group experienced a reduction in magnesium sulfate 
administration, as well as reduced mean time spent receiving nursing care (23.00 versus 
70.13 minutes, P<0.001 (Darngawn et al., 2012, p. 237-238). Vigil-De Garcia, Ramirez, 
Duran & Quintero (2017) also tested a 6-hour treatment course; however, their study 
required that patients receive less than 8-hours of magnesium sulfate treatment before 
delivery (p. 1). Comparable to other studies examining the 6-hour treatment time no 
differences were found between the study groups regarding the incidence of eclampsia 
(Vigil-De Garcia et al., 2017, p. 3). It was also suggested that a minimum dose of 14-
grams of magnesium sulfate versus the 32-gram dose administered during the traditional 
24-hour treatment is as effective in preventing seizures (Vigil-De Garcia, 2017, p. 5). 
 In addition to exploring the benefits of a 6-hour treatment course, preceding 
scholars have examined the effectiveness of a less extreme reduction in treatment time to 
12-hours. Anjum et al. (2016a) compared study groups who received the traditional 24-
hour treatment course of magnesium sulfate and the abbreviated 12-hour course (p. 68). 
Researchers found that there was no statistically significant difference between study 
groups regarding clinical and demographic characteristics (Anjum et al., 2016a, p. 69). 
Neither group exhibited seizures or toxicity after the completion of treatment; however, 
the control group receiving the traditional 24-hours of magnesium sulfate experienced ten 
seizures after two hours of therapy (Anjum et al., 2016a, p. 69). However, statistically 
significant differences were seen between the two groups when considering the 
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secondary outcomes including length of hospital stay (Study group: 5.3 ± 0.8 days, 
Control group: 7.5 ± 1.5 days; P<0.001) and days with a Foley catheter Study group: 19.6  
± 2.5 hours, Control group: 31.5 ± 3.2 hours, P<0.001)(Anjum et al., 2016a, p. 70). The 
group who received the 24-hour treatment course was shown to have received a higher 
dose of magnesium sulfate (Study group: 23.2 ± 2.8 grams; Control group: 34.9 ± 3.2 
grams; P<0.001) when compared to the intervention group (Anjum et al., 2016a, p. 70). 
Maia et al. (2014) also examined a 12-hour treatment course to the 24-hour treatment 
course and observed similar results. All study participants received an IV infusion of 
magnesium sulfate at 1-gram per hour for the first 12-hours after delivery (Maia et al., 
2014, p. 261). Once the initial 12-hours had passed the infusion was discontinued for 
participants in the intervention group while the control group continued to receive the 
magnesium sulfate for the full 24-hours (Maia et al., 2014, p. 261). Similar to preceding 
studies, the reduced treatment time of 12-hours was as effective in preventing seizures 
during the first 24-hours after delivery (Maia et al., 2014, p. 261). Additionally, the 
magnesium sulfate did not need to be restarted for the incidence of eclampsia (Maia et 
al., 2014, p. 261). Along with participant treated adequately for the prevention of 
seizures, there was also a substantial reduction in the time participants had a Foley 
catheter (14.3 hours vs 25.3 hours; P<0.001), time to ambulation (18.8 hours vs 25.8 
hours; P<0.001), and time to bond with baby (29.6 hours vs 35.0 hours; p=0.03) (Maia et 
al., 2014, p. 263). With the reduction in time to have contact with the baby, there could 
be an improvement in the “likelihood of establishing breastfeeding” (Maia et al., 2014, p. 
263). 
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 Kashanian et al. (2016) performed a similar study in investigating the 
effectiveness of a shortened treatment time of magnesium sulfate for 12-hours as 
compared to 24-hours for patients with severe preeclampsia (p. 2282). Baseline 
demographic and clinical characteristics were similar between both groups (Kashanian et 
al., 2016, p. 2283). Laboratory values including AST, ALT, alkaline phosphatase, 
hemoglobin, platelet count, BUN, and creatinine before and after treatment were 
compared between both groups and no significant difference was observed (Kashanian et 
al., 2016, p. 2283). In addition to comparing laboratory values, researchers also compared 
both groups for the incidence of side effects often associated with magnesium sulfate 
treatment and the transition to eclampsia including “flushing, nausea and vomiting, head 
lightness, headache, blurred vision, and epigastric pain” (Kashanian et al., 2016, p. 2286). 
There was no significant difference seen between the two groups concerning the adverse 
effects (Kashanian et al., 2016, p. 2286).  
 El-Khayat, Atef, Abdelatty, & El-semary (2016) compared all three methods, the 
loading dose alone, the abbreviated 12-hour course and the 24-hour course, in their 
capability of preventing seizures in patients with preeclampsia (p. 154). All three groups 
exhibited no statistically significant difference in baseline demographic and clinical 
characteristics (El-Khayat et al., 2016, p. 155). There was also no statistically significant 
difference in blood pressure, the incidence of hemorrhage, and type of delivery (El-
Khayat et al., 2016, p. 155). Additionally, there were no statistically significant 
differences seen in neonatal outcomes between the three groups, including “prematurity, 
IUGR, perinatal death and NICU admission (El-Khayat et al., 2016, p. 155). In 
considering the primary outcome of eclampsia, there was no statistically significant 
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difference found between the three groups (El-Khayat et al., 2016, p. 155). There was, 
however, statistically significant differences noted between the three groups when 
considering the incidence of flushing, an adverse effect of magnesium sulfate treatment 
(El-Khayat et al., 2016, p. 155). Researchers concluded that following a protocol that 
requires a loading dose only would require “less maternal monitoring for urine output and 
blood pressure” (El-Khayat et al., 2016, p. 158). 
Many of these studies shared comparable primary outcome measures that focused 
on the incidence of seizure activity or the recurrence of seizures. However, there was 
more variability seen in the secondary outcome measures which put the spotlight on 
clinical characteristics such as laboratory findings, participant recovery, maternal and 
neonatal outcomes, reports of pain, and time spent on monitoring by healthcare staff. The 
strength of these studies lies in the study design. Each study discussed was a randomized 
controlled trial. While most were single-blinded, El-Kayat et al. (2016) managed to 
maintain a double-blinded investigation adding to its strength (p. 154). The primary 
limitation of research investigating the effectiveness of an abbreviated treatment course 
of magnesium sulfate in preventing seizures in patients with preeclampsia is the sample 
size. Sample sizes of the previously mentioned studies ranged from 98 participants to 284 
participants. Maia et al. (2014) recognized that larger sample sizes would be needed to 
observe the frequency of eclampsia in patients with a reduced treatment time of 
magnesium sulfate (p. 263). Specifically, the involvement of multiple facilities and 
upward of 18,000 participants would be necessary to have sufficient power to make a 
recommendation for practice change (Maia et al., 2014, p.263). Another limitation of 
these studies was the lack of measurement tools involved to standardize reportable data. 
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Darngawn et al. (2012) was the only study that made mention of an established 
measurement tool, the Wong-Bake pain scale, to standardize the participants’ reports of 
pain (p. 238). Maia et al. (2014) utilized a Likert scale to measure the participant’s 
satisfaction with the care she receiving (p. 261). All other studies relied merely on self-
report from participants. 
 The Johns Hopkins Nursing Evidence-Based Practice Model (JHNEBP) will be 
utilized to implement this project. The JHNEBP Model relies on “practice, education, and 
research” as its pillars for professional nursing (Dearholt & Dang, 2012, p. 34). “The 18-
step JHNEBP process occurs in 3 phases and can be simply described as Practice 
question, Evidence, and Translation (PET)” (Dearholt & Dang, 2012, p. 42). The 
JHNEBP Model walks the professional nurse through the process of implementing 
change within their organization, “provides tools for process and critique, including 
question development, evidence rating scale, and research and non-research evidence 
appraisal” (Schaffer, Sandau, & Diedrick, 2013). 
Method 
Design   
The overall approach of this project will be that of change implementation. The 
primary goal will not be implementing the change itself but assessing the willingness of 
physicians to change current practice. A quality improvement design was utilized to 
evaluate the effectiveness of the intervention. Each group of physicians was presented the 
same survey, and no randomization occurred. A one group pretest-posttest design was 
conducted to determine if the research-based education had an impact on the physicians’ 
willingness to change current practice. 
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Setting  
This project took place on a sizable academic medical campus located in the city, 
as well as the offices of private physician groups. Conference rooms were utilized as 
arranged with administrative assistants and the physicians themselves. 
Sample 
A convenience sample of obstetric physicians that care for patients at Barnes-
Jewish Hospital served as the sample population. The experience level of the physicians 
ranged from residents, year one through year four, fellows, attending physicians, and 
nurse practitioners. There are roughly 32 obstetric residents. In addition to the residents, 
there are two laborists,  four Women’s Health Nurse Practitioners (WHNP) and several 
groups of private attending physicians. The goal was to have at least 30 providers in the 
sample population.  
Approval Processes 
 Since project work took place at Barnes-Jewish Hospital, a project proposal was 
submitted to the Department of Research’s Protocol Review Committee. Because the 
proposed study methods do not include Barnes-Jewish Hospital team members who fall 
under the purview of Patient Care Services, it was not necessary to participate in the 
Proposal Review Committee process. Additionally, an application was submitted through 
the University of Missouri-St. Louis Internal Review Board and the study was deemed 
exempt. Risks to participants included slight discomfort if personal views were 
challenged in the group discussion. Ethical considerations were centered around 
protecting the confidentiality and anonymity of participants. While there is always a risk 
of breach of confidentiality, every effort to preserve privacy was maintained. No names 
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were written on the surveys and only identified by a prewritten number. Care was taken 
to ensure that responses remained confidential by having physicians place their responses 
in blank envelopes. Participation was voluntary and implied consents acknowledged with 
the receipt of the surveys.  
Procedures 
 Providers caring for obstetric patients at Barnes-Jewish Hospital were enrolled 
between March 22, 2018, and May 22, 2018. A physician champion was identified to 
help organize appropriate meeting times, as well as ensure the educational material was 
suitable for presenting to the providers. Before the educational sessions, packets were 
made for each participant that included the implied consent form, a brief synopsis of the 
evidence as well as the surveys taken before and after the presentation. An unspecified 
number of meetings were planned with each session not lasting longer than 30 minutes. 
Providers were contacted to schedule time for the primary investigator to present the 
research-based educational sessions where evidence that supports the possible change in 
practice from treating preeclampsia with 24-hours of magnesium sulfate to reduced time 
of 12-hours was presented. Each provider received an information sheet, and their survey 
completion implied their understanding of the research and consent to participate (see 
Appendix C). Physicians were asked to complete a questionnaire before and after the 
presentation. Physicians were not required to include their name on the surveys, and they 
were left in an unmarked envelope to preserve anonymity and left in a specified location. 
Data Collection/Analysis 
 Self-reported questionnaires were administered to providers before the session 
and then immediately after to determine if the research-based educational session had an 
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impact on the providers’ willingness to change the current prescribing of magnesium 
sulfate treatment courses. Both the pre-test survey and the post-test survey had nine 
questions which were identical. Both pre-test and post-test survey’s asked the physicians 
to identify what level provider they are with choices being resident, fellow, attending, or 
nurse practitioner. The questionnaires were brief and focused on the providers prior 
knowledge of magnesium sulfate treatment courses, if the session introduced new 
information, beliefs on various concepts of care of the preeclamptic patient, and if the 
evidence presented encouraged them to change prescribing behaviors (see Appendices A 
and B for examples of surveys). A paired t-test using SPSS version 24 (IBM, Armonk, 
NY, USA) was anticipated to be utilized to determine if there is a statistically significant 
difference between the willingness to change practice before and after the intervention. 
Furthermore, a Chi-square test was utilized to determine if any association existed 
between provider level and change in variables. 
 A manual chart review of patients receiving magnesium sulfate between December 15, 
2016, through December 21, 2,018 was conducted with the assistance of the clinical 
pharmacist. Extracted data from a hospital computer included the date of the prescribed 
medication to note the frequency of prescription, the level of the provider prescribing the 
medication to gain an understanding of who is most frequently ordering the medication 
and the duration of the treatment. Because special privileges were necessary to access 
Centricity GE, additional data to determine the duration of treatment was unable to be 
obtained. Identifiable data was not utilized or recorded. Data was entered and analyzed 
on a spreadsheet. That list was used to determine the dates of treatment to identify the 
frequency of magnesium sulfate ordering for preeclampsia as well as the provider level. 
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Results 
 A manual chart review of physician orders of magnesium sulfate for postpartum 
preeclampsia resulted in a total of 811 orders, which averages 16 orders per week. Of 
those 811 orders, 93% of them were entered by OB residents with the majority of the 
ordering being completed by second-year and fourth-year residents. The remaining 7% of 
orders represented fellows, nurse practitioners, laborists, service attending physicians, 
and private service attending physicians. The OB residents are primarily responsible for 
entering orders for patients’ which explains the high percentage of magnesium sulfate 
orders completed by residents. The majority of preeclampsia diagnoses are made on the 
antepartum unit where second-year residents reside, while the fourth-year residents are 
chief residents who primarily manage the treatment plans on all obstetric patients. 
Understanding of the residents’ rotation helps to explain the distribution of medication 
orders. 
In the present quality improvement project, a convenience sample of 49 providers 
was surveyed. Among those 49 providers, 26 were residents, 5 were fellows, 15 were 
attendings, and 3 were nurse practitioners (see appendix D). A paired-samples t-test was 
used to determine whether there was a statistically significant mean difference between 
survey answers after participants listened to an educational presentation (see Appendix 
E). Statistically significant differences were observed regarding the disruptive role a 24-
hour course of magnesium sulfate plays in breastfeeding and maternal-infant bonding 
(M=.878, SD=1.130, t=5.437, p=.000) and the necessity of the patient to have a Foley 
catheter allowing nursing to adequately monitor for magnesium sulfate toxicity (M=.571, 
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SD=1.258, t=3.179, p=.003). While there was a change in the perception that patients 
should be kept on strict bedrest while receiving this high-risk medication, it was not 
statistically significant (M=-.102, SD=.368, t=-1.943, p=.058). A Fisher’s Exact test was 
conducted between provider level and the belief that a patient should remain on bedrest 
for the duration of treatment. There was no statistically significant association between 
provider level and idea that a patient should stay on bedrest for the duration of treatment, 
(p=.066) (see Appendix F, Figure 1). 
There was a significant difference in the scores for the necessity for patients to 
receive a full 24-hours of magnesium sulfate (M=-.347, SD=1.011, t=-2.401, p=.020) and 
if patients with stable preeclampsia could benefit from an abbreviated magnesium sulfate 
course (M=.449, SD=1.209, t=2.600, p=.012). While providers appeared to be more 
accepting of an abbreviated treatment course of magnesium sulfate in managing patients 
with preeclampsia, there was not a statistically significant difference seen in the 
providers’ willingness to prescribe a 12-hour course of magnesium sulfate (M=0.41, 
SD=1.258, t=.227, p=.821). Because the mean difference was not statistically significant, 
we can reject the alternative hypothesis and accept the null hypothesis. 
A chi-square test for association was conducted to determine if there were any 
differences in willingness to change prescribing behavior between residents and 
attendings. The data was analyzed for both pretest and posttest surveys. A response of 
“unsure” was considered to be a “no” for this analysis. All expected cell frequencies were 
greater than five for pretest results. There was no statistically significant association 
between provider level and willingness to prescribe a reduced treatment course on the 
pretest, x2(1) = .360, p = .548 (see Appendix F, figure 2). Posttest results exhibited an 
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expected cell frequency of four in which case a Fisher’s Exact test was conducted. Again, 
there was not a statistically significant association noted between provider level and 
willingness to prescribe a reduced treatment course, p = .064 (see Appendix F, figure 3). 
While attending physician responses remained consistent pretest and posttest, an 
unexpected increase in the number of resident physicians unwilling to change their 
prescriptive behavior was observed posttest. These results suggest that while the 
education presented had an impact on the providers ability to understand various 
implications experienced by patients receiving 24-hours of magnesium sulfate, ultimately 
providers are not yet committed to prescribing reduced treatment courses of magnesium 
sulfate (see Appendix G). 
Discussion 
 
This study revealed that there was no statistically significant difference in the 
willingness of the providers to prescribe a reduced treatment course of magnesium sulfate 
for postpartum patients with preeclampsia (p=.821) . However, there was a statistically 
significant difference noted between the providers concerning the belief that postpartum 
magnesium sulfate could be reduced from the traditional 24-hour treatment course 
(p=.020). Providers also responded well to the notion that patients that present with 
preeclampsia without severe features could, in fact, benefit from an abbreviated treatment 
course (p=.012). This lack of correlation highlights that while providers are open to the 
concept of a reduced treatment course, they are not yet committed to a change in 
treatment plan.  
This study began with the primary investigator’s concern for patient safety while 
they were being allowed out of bed and off the hospital unit while receiving this high-risk 
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medication infusion. Additionally, these patients were lacking a Foley catheter, which 
decreases the ability of the nurse to monitor for magnesium sulfate adequately. It is 
imperative to strictly monitor the patient’s urine output to ensure that they have adequate 
diuresis (30 mL/hr) as oliguria (>30 mL/hr) leads to the buildup of magnesium sulfate 
leading to toxicity (Murray & McKinney, 2010). If a patient is allowed off the hospital 
unit without a Foley catheter, the nurse is unable to monitor their urine output. While 
there was a statistically significant difference observed in the providers belief that a 
patient should have a Foley catheter while being treated with magnesium sulfate 
(p=.003), there was no difference noted in their belief that these patients should remain 
on strict bedrest until treatment is complete (p=.058). 
From discussions had with providers after the presentations, the primary 
investigator noticed a range of opinions regarding the management of these patients. 
Overall, most of the attending physicians were unaware that patients with preeclampsia 
treated with magnesium sulfate were being allowed off the unit with the infusion running; 
furthermore, they were unaware that these same patients were without a Foley catheter. 
Resident physicians are primarily responsible for managing the care of these patients 
throughout their hospital stay with the guidance of the attending physicians which could 
explain the lack of awareness. At the time of the completion of this study, there has been 
recent communication with a Maternal-Fetal Medicine (MFM) physician that there are 
changes to come regarding managing postpartum patients with preeclampsia receiving 
magnesium sulfate. Additionally, the Director of the Residency Program communicated 
the same sentiment to the resident physicians. Further discussion with the Washington 
University Obstetric Physician group highlighted that these patients requiring a higher 
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level of care are included in the nurses assignment of six to eight patients, including 
mothers and newborns. It became clear that the obstetric providers were unaware of the 
acuity level of the postpartum nursing assignments as they were only aware that these 
patients received one-to-one care on the labor and delivery unit. 
An opportunity exists to standardize patient education through their journey from 
labor and delivery to the postpartum unit. As stated above, since these patients receive 
one-to-one care from the labor and delivery nurse there is more opportunity for the 
patient to be taken to see their baby in the neonatal intensive care unit (NICU) by their 
nurse, as well as receive closer monitoring. The labor and delivery staff, nursing and 
providers, lead these patients to expect the same level of care when they transfer to the 
postpartum unit without consideration to the staffing differences as well as increased 
acuity. As this project comes to an end work is in progress to update current nursing 
policies that address the management of care of patients receiving magnesium sulfate. 
Additionally, patient education is being standardized to ensure these patients expectations 
are managed and safety ensured throughout their stay. It is the plan of the primary 
investigator to collect additional data to determine if patients receiving magnesium 
sulfate present to the postpartum unit with Foley catheters and remain on strict bedrest 
after presenting to the obstetric providers. 
Conclusion  
 While obstetric providers seem to be open to the idea of an abbreviated treatment 
course of magnesium sulfate, they are not yet comfortable with changing their 
prescriptive behavior. Given this fact, further research is necessary to show the clinical 
benefits of an abbreviated treatment course of magnesium sulfate. This study highlights 
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that the management of care for postpartum patients with preeclampsia receiving 
magnesium sulfate can be improved. While not necessarily indicated by survey results, 
providers are now aware of the risk these patients are at for experiencing adverse health 
outcomes due to being allowed off the unit and not having a Foley catheter throughout 
treatment time.  
 Work to standardize patient education is being done so that staff on labor and 
delivery and postpartum are providing the same information to the patients to manage 
their expectations throughout their stay. Dissemination of staff education will occur at the 
annual Women & Infant’s Skills Day in conjunction with a presentation by the clinical 
pharmacist on medication information for magnesium sulfate. Creating a partnership with 
the Washington University Obstetric Physicians, as well as the Maternal-Fetal Medicine 
Physicians, could help fill the gaps in the perception of the nursing care provided on the 
postpartum unit for the patients on magnesium sulfate. Follow-up is expected to occur 
with Maternal-Fetal Medicine as a physician with the Washington University Obstetric 
group found that this study would make an exceptional Fellow project. Continued efforts 
with Maternal-Fetal Medicine could help provide the additional research to support 
further a reduced treatment course of magnesium sulfate for patients receiving 
magnesium sulfate. 
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Appendix D 
 
 
 
 
Figure 1: Sample population by provider level 
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Appendix E 
 
 
 
 
Table 1: Paired t-test results for survey responses. P values less than .05 were considered significant. 
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Appendix F 
 
Table 1: Association between provider level and belief that patients’ should remain on bedrest 
 
 
Table 2: Pretest association between provider level and willingness to change prescribing behavior 
 
 
 
Table 3: Posttest association between provider level and willingness to change prescribing behavior 
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Appendix G 
 
Graph 1: Provider level and willingness to change prescriptive behavior pretest 
 
 
Graph 2: Provider level and willingness to change prescriptive behavior posttest 
